Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-337-4680
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees111
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions
What is Solid Biosciences' stock symbol?
Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."
How were Solid Biosciences' earnings last quarter?
Solid Biosciences Inc (NASDAQ:SLDB) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.81) by $0.05. View Solid Biosciences' Earnings History.
When is Solid Biosciences' next earnings date?
What price target have analysts set for SLDB?
8 brokers have issued 12-month price objectives for Solid Biosciences' stock. Their predictions range from $4.00 to $22.00. On average, they anticipate Solid Biosciences' share price to reach $10.50 in the next year. This suggests that the stock has a possible downside of 3.0%. View Analyst Price Targets for Solid Biosciences.
What is the consensus analysts' recommendation for Solid Biosciences?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.
What are Wall Street analysts saying about Solid Biosciences stock?
Here are some recent quotes from research analysts about Solid Biosciences stock:
- 1. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (9/28/2019)
- 2. Chardan Capital analysts commented, "We thus now upgrade SLDB from Neutral to Buy, increasing our PT from $7.50 to $10, ahead of Solid’s anticipated IGNITE DMD data update later this year. The risks surrounding SGT-001 are well-known to the market, and any improvements in the market’s view of SGT-001 safety and/or efficacy (e.g. with the IGNITE DMD data update later this year) could lead to significant share price momentum. Recall, Solid has reported adverse events in prior patients dosed with SGT-001. Solid announced the FDA placed a clinical hold on the IGNITE trial after a patient experienced decreased platelet counts, evidence of complement activation and reduced blood cell counts." (8/16/2019)
Has Solid Biosciences been receiving favorable news coverage?
News stories about SLDB stock have been trending neutral this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Solid Biosciences earned a news impact score of 0.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Solid Biosciences.
Are investors shorting Solid Biosciences?
Solid Biosciences saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 3,320,000 shares, a decline of 11.0% from the August 15th total of 3,730,000 shares. Based on an average trading volume of 560,200 shares, the short-interest ratio is currently 5.9 days. Approximately 11.0% of the shares of the stock are sold short. View Solid Biosciences' Current Options Chain.
Who are some of Solid Biosciences' key competitors?
Some companies that are related to Solid Biosciences include Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG) and Twist Bioscience (TWST).
What other stocks do shareholders of Solid Biosciences own?
Who are Solid Biosciences' key executives?
Solid Biosciences' management team includes the folowing people:
- Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
- Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
- Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
- Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
- Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)
When did Solid Biosciences IPO?
(SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.
How do I buy shares of Solid Biosciences?
Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Solid Biosciences' stock price today?
One share of SLDB stock can currently be purchased for approximately $10.83.
How big of a company is Solid Biosciences?
Solid Biosciences has a market capitalization of $498.18 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.
What is Solid Biosciences' official website?
How can I contact Solid Biosciences?
Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.
MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
